WGBS WaferGen Bio-Systems, Inc. featured news, full reports, and detailed charts
WaferGen Bio-Systems, Inc. (WGBS/WGBS.OB) Wrap Up:
WaferGen Biosystems, Inc., a development stage company, engages in the development, manufacture, and sale of systems for gene expression, genotyping, and stem cell research for the life sciences, pharmaceutical drug discovery, and biomarker discovery and diagnostic products industries. It offers SmartSlide Micro-Incubation system that provides a controlled environment and physiological conditions for imaging studies, allowing researchers to characterize, differentiate, and proliferate various cells, as well as provides growth conditions for stem and primary cells. The company also develops the SmartChip Real Time PCR System, which allows identification of the expressed genes. WaferGen offers...www.wafergen.com
32 Employees
Founded in 2002
WaferGen Bio-Systems, Inc. (WGBS:OTC Bulletin Board Market)
LAST $1.55 USD
CHANGE TODAY 0.00 0.00%
VOLUME 11.2K
As of 3:09 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of WaferGen Bio-Systems, Inc. (WGBS)
|
OPEN
$1.55
|
PREVIOUS CLOSE
$1.55
|
|
|
DAY HIGH
$1.55
|
DAY LOW
$1.53
|
|
|
52 WEEK HIGH
09/10/09 - $2.20
|
52 WEEK LOW
12/22/08 - $0.56
|
|
|
MARKET CAP
46.5M
|
AVERAGE VOLUME 3 mo
4.0K
|
|
|
DILUTED EPS TTM
$-0.35
|
SHARES OUTSTANDING
30.0M
|
|
|
WGBS Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
WGBS Top Compensated Officers
Mr. Alnoor Shivji
Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $317.5K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for WaferGen Bio-Systems, Inc. (WGBS)
WaferGen Biosystems to Introduce New Service for Gene-Expression Profiling
11/19/2009
WaferGen Biosystems Inc. announced a new, innovative service for gene-expression profiling of thousands of genes using the SmartChip(TM) Real-Time PCR System. By taking advantage of the SmartChip Real-Time PCR system, WaferGen will offer universities, pharmaceutical and diagnostic companies a service that utilizes pathway-specific gene panels to discover and validate new biomarkers. The company also announced that it is moving to a new facility to support the SmartChip services and the expansion of manufacturing and R&D functions. The new WaferGen SmartChip Service will be made available to a few select customers in December and made more broadly available in the first quarter of 2010. The SmartChip Service offerings will be expanded early next year to include a miRNA expression panel. The WaferGen SmartChip Service is targeted at scientists involved in the discovery and validation of molecular biomarkers. The initial product to be run on the SmartChip platform is the SmartChip Human Oncology Gene Panel that provides pathway based gene expression profiling for Oncology.
WaferGen Biosystems Inc. Names Hector Brush as Principal Financial Officer
11/12/2009
The Board of Directors of WaferGen Biosystems Inc. confirmed, approved and ratified Hector Brush's position as the company's Principal Financial Officer on November 4, 2009. Mr. Brush has served as the company's Treasurer since the departure of Amjad Huda, the company's former Chief Financial Officer and Treasurer, on June 17, 2009. Mr. Brush had served as its senior accountant since November 1, 2007.
WaferGen Biosystems Inc., Annual General Meeting, Dec 04, 2009
11/12/2009
WaferGen Biosystems Inc., Annual General Meeting, Dec 04, 2009, at 09:00 US Pacific Time. Location: Fremont Marriott in Silicon Valley, 46100 Landing Parkway, Fremont, CA 94538,United States. Agenda: To elect seven directors to serve for a one-year term until the 2010 annual meeting of stockholders or until their successors are duly elected and qualified; to amend the WaferGen Bio-systems Inc., 2008 Stock Incentive Plan to increase the number of shares of the Company's common stock that may be issued pursuant to awards thereunder from 2,000,000 shares to 3,500,000; to ratify the selection of Rowbotham & Company LLP as the Company's independent auditors to provide audit services to the Company for the fiscal year ending December 31, 2009; and to transact such other business as may properly come before the annual meeting or any adjournment or postponement thereof .
WGBS Competitors
| Company | Last | Change | |
| No competitor information is available for WGBS. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | WGBS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 105.2x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 109.4x |
|
|
WGBS |
||
|
WGBS transactions
| Type Date |
Target |
|
Private Placement
June 16, 2009 |
-- |
More Recent News About WaferGen Bio-Systems, Inc.
More news for WGBS
WAFERGEN BIO-SYSTEMS, INC. Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion highlights the principal factors that have affected our financial condition and results of operations as well as our liquidity and capital resources for the periods described. The information contained in this Form 10-Q is intended to update the information contained in our annual report on Form 10-K for the year ended December 31, 2008, as amended, (the "Form 10-K"), and our quarterly report on Form 10-Q for the quarters ended March 31 and June 30, 2009 (the "First and Second Quarter Forms 10-Q"), both as filed with the Securities and Exchange Commission, and presumes that readers have access to, and will have read, the "Management's Discussion and Analysis of Financial Condition and Results of Operation," our consolidated financial statements and the notes thereto, and other information contained in the Form 10-K and First and Second Quarter Forms 10-Q. The following discussion and analysis also should be read together with our condensed consolidated financial statements and the notes to the condensed consolidated financial statements and the notes thereto included elsewhere in this Form 10-Q. Forward-Looking Statements Information included in this Form 10-Q may contain forward-looking statements. Except for the historical information contained in this discussion of the business and the discussion and analysis of financial condition and results of operations, the matters discussed herein are forward looking statements. These forward looking statements include but are not limited to the Company's plans for sales growth and expectations of gross margin, expenses, new product introduction, and the Company's liquidity and capital needs. This information may involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different fro...Click here to read the whole Article (external link)
WAFERGEN BIO-SYSTEMS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
Show all filings for WAFERGEN BIO-SYSTEMS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for WAFERGEN BIO-SYSTEMS, INC. 12-Nov-2009Change in Directors or Principal Officers, Other Events Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as...Click here to read the whole Article (external link)
WAFERGEN BIO-SYSTEMS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
Show all filings for WAFERGEN BIO-SYSTEMS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for WAFERGEN BIO-SYSTEMS, INC. 2-Nov-2009Change in Directors or Principal Officers, Financial Statements and Ex Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information...Click here to read the whole Article (external link)
WaferGen Adds Robert Coradini, Former President of J&J New Ventures, to Board of Directors
FREMONT, Calif., Oct. 28 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS - News), a leading developer of state-of-the-art genetic analysis systems, today announced that Robert Coradini has joined the WaferGen Board of Directors. Mr. Coradini was most recently the President, New Ventures of Johnson & Johnson Consumer Group of Companies (2004-2009). He joined J&J in 1996 and has served as the Chief Executive and President of various subsidiaries including: Lifescan, Cordis Endovascular, OrthoNeutrogena, Cardiovations (Ethicon), and was the head of Business Development for the Medical Devices & Diagnostics Group. Prior to joining J&J, Mr. Coradini was business manager for GE Medical Systems, Inc. "I believe WaferGen's revolutionary technology for gene expression and biomarker discovery, especially in wound healing and other diseases like cancer, is a breakthrough for medicine and could greatly advance drug development for companies such as J&J," said Robert Coradini. "Just as faster and more powerful computers unleashed the power of the Internet, I expect that WaferGen's Real-Time PCR technology will unleash new, undiscovered information on genomics and that the speed of processing will have a major positive impact on identifying individual treatment options for prescribers and patients.""We are delighted that Bob has joined WaferGen's Board and I look forward to working with him as we move from the development phase to full commercialization of our Real-Time PCR System...Click here to read the whole Article (external link)
WaferGen to Present at the 8th Annual Bio Investor Forum 2009
FREMONT, Calif., Oct. 20 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS - News), a leading developer of state-of- the-art genetic analysis research tools, today announced that Mr. Alnoor Shivji, Chairman and Chief Executive Officer, will deliver a corporate presentation at the Bio Investor Forum 2009. The conference will be held October 28 - 29, 2009, at the Palace Hotel in San Francisco. Mr. Shivji's presentation will take place at 2:30 p.m. on Thursday October 29 in Twin Peak North conference room. The presentation will include an overview of the company's SmartChip system, which has been used successfully at the University of Pittsburg Medical Center (UPMC). As a result of the positive data, WaferGen has initiated multiple collaborations with academic research centers in the US, Europe and Japan.About WaferGenWaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping for the life science and pharmaceutical industries. The company is actively developing its SmartChip product for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform and promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets.Forward-Looking StatementsThis press release may contain certain "forward-looking statements". Su...Click here to read the whole Article (external link)
WaferGen raises $6.2M in private placements
ONLINE: home | business news | small business | sales & marketing | real estate | events | community | careers | city guide | advertise | about us | rss PRINT: subscribe | renew | advertise | book of lists | business intelligence | ...Click here to read the whole Article (external link)
WaferGen Biosystems raises $6.2M
ONLINE: home | business news | small business | sales & marketing | real estate | events | community | careers | city guide | advertise | about us | rss PRINT: subscribe | renew | advertise | book of lists | business intelligence | classifieds | view digital edition | ...Click here to read the whole Article (external link)
WAFERGEN BIO-SYSTEMS, INC. Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
Would you like to leave a comment about WaferGen Bio-Systems, Inc. WGBS/WGBS.OB
Find out what social network information about WaferGen Bio-Systems, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides WaferGen Bio-Systems, Inc. there is more great information available at Realpennies.com